The point being is that the incidence of hospitalization for CHF was in its own category, pre-specified secondary endpoint within the BOM trial. (you can correct me if I am wrong here) 

According to slide 16, it shows a Hazard Reduction of 41% and a P-Value 0.03.

Is this not sufficient enough for HL to manufacture RVX208 as they see fit for China? They would need to pursue on their own FDA China equivalent. (NMPA) 

Koo